LRP6 and Alzheimer disease: Therefore, as proposed for AD, Wnt activators that restore Wnt/β-catenin signalling in brain, particularly those targeting Wnt antagonist DKK1 and Wnt receptor LRP6, could represent novel therapeutic tools for migraine treatment.